SCHEMBL5138025

SCHEMBL5138025

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ C5AR1 P21730 1/20 0.47
▸ TSHR P16473 5/20 0.47
▸ CRHR1 P34998 4/20 0.41
▸ KDM4E B2RXH2 6/20 0.40
▸ ALDH1A1 P00352 6/20 0.40
▸ HPGD P15428 6/20 0.40
▸ HSD17B10 Q99714 6/20 0.40
▸ NR1H3 Q13133 1/20 0.40
▸ CYP3A4 P08684 5/20 0.39
▸ PDE4B Q07343 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135570 0.95 C5AR1 (0.48) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL649161 0.95 C5AR1 (0.47) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5135106 0.94 C5AR1 (0.47) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5136173 0.94 C5AR1 (0.47) C5AR1TSHRCRHR1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL648480 0.94 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL651094 0.94 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5136220 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5136560 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5135043 0.92 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL5137962 0.92 C5AR1 (0.44) C5AR1TSHRCRHR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 — — EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 — — EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 — — WO disclosed
Send feedback